SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?


To: Steve Fancy who wrote (4922)7/21/1998 4:42:00 PM
From: Peter Singleton  Respond to of 6136
 
more stuff to chew on ... BARS estimates as of 4/15, no idea what they were estimating going into the announcement.

I don't have any opinion yet on the earnings, nor on the oncology division announcement ... too much to sift through. Obviously, US sales beat estimates by a bit. No feel yet for all the other income statement, balance sheet, cash flow stuff that the analysts have to sift through to assess things.

ESTIMATE REVISIONS:
AGPH: BANCAM/ROB STEP increased estimate for fiscal year
ending 06/98 from $0.85 to $0.91 on 04/15/98
AGPH: BANCAM/ROB STEP increased estimate for quarter ending
06/98 from $0.21 to $0.24 on 04/15/98